Quantitative benefit-risk modelling of infliximab biosimilar inflectra versus reference product remicade in the treatment of Crohn's disease

被引：0
|
作者：
Catt, Heather [1 ]
Hughes, Dyfrig [2 ]
Bodger, Keith [1 ]
Kirkham, Jamie [1 ]
机构：
[1] Univ Liverpool, Liverpool, Merseyside, England
[2] Univ Bangor, Bangor, Gwynedd, Wales
来源：
TRIALS | 2017年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
P143
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Improvement of arthritis and arthralgia after treatment with infliximab (remicade) in a German prospective, open-label, multicenter trial in refractory Crohn's disease
    Herfarth, H
    Obermeier, F
    Andus, T
    Rogler, G
    Nikolaus, S
    Kuehbacher, T
    Schreiber, S
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2002, 97 (10): : 2688 - 2690
  • [42] Safety and efficacy of infliximab biosimilar (Remsima©) in Crohn's disease patients in clinical practice: results after 6 months of treatment
    Guerra Veloz, M. F.
    Arguelles Arias, F.
    Perea Amarillo, R.
    Castro Laria, L.
    Maldonado Perez, M. B.
    Benitez Roldan, A.
    Merino, V.
    Ramirez, G.
    Vilches Arenas, A.
    Caunedo Alvarez, A.
    JOURNAL OF CROHNS & COLITIS, 2016, 10 : S328 - S329
  • [43] Early Diagnosis and Treatment of Postoperative Endoscopic Recurrence of Crohn’s Disease: Partial Benefit by Infliximab—A Pilot Study
    Dario Sorrentino
    Giovanni Terrosu
    Alberto Paviotti
    Marco Geraci
    Claudio Avellini
    Giorgio Zoli
    Walter Fries
    Silvio Danese
    Pietro Occhipinti
    Tiziano Croatto
    Dimitra Zarifi
    Digestive Diseases and Sciences, 2012, 57 : 1341 - 1348
  • [44] Early Diagnosis and Treatment of Postoperative Endoscopic Recurrence of Crohn's Disease: Partial Benefit by Infliximab - a Pilot Study
    Sorrentino, Dario
    Terrosu, Giovanni
    Paviotti, Alberto
    Geraci, Marco
    Avellini, Claudio
    Zoli, Giorgio
    Fries, Walter
    Danese, Silvio
    Occhipinti, Pietro
    Croatto, Tiziano
    Zarifi, Dimitra
    GASTROENTEROLOGY, 2012, 142 (05) : S64 - S64
  • [45] Clinical Practice of Adalimumab and Infliximab Biosimilar Treatment in Adult Patients With Crohn's Disease (vol 27, pg 1367, 2021)
    Reinisch, Walter
    Gecse, Krisztina
    Halfvarson, Jonas
    Irving, Peter M.
    Jahnsen, Jorgen
    Peyrin-Biroulet, Laurent
    Rogler, Gerhard
    Schreiber, Stefan
    Danese, Silvio
    INFLAMMATORY BOWEL DISEASES, 2021, 27 (08) : 1367 - 1367
  • [46] Clinical Practice of Adalimumab and Infliximab Biosimilar Treatment in Adult Patients With Crohn's Disease (vol 27, pg 106, 2021)
    Daneses, Silvio
    JOURNAL OF ANIMAL SCIENCE, 2022, 100 (09) : 1367 - 1367
  • [47] Development of pulmonary sarcoidosis in Crohn’s disease patient under infliximab biosimilar treatment after long-term original infliximab treatment: a case report and literature review
    Shin Kashima
    Kentaro Moriichi
    Katsuyoshi Ando
    Nobuhiro Ueno
    Hiroki Tanabe
    Sayaka Yuzawa
    Mikihiro Fujiya
    BMC Gastroenterology, 21
  • [48] Development of pulmonary sarcoidosis in Crohn's disease patient under infliximab biosimilar treatment after long-term original infliximab treatment: a case report and literature review
    Kashima, Shin
    Moriichi, Kentaro
    Ando, Katsuyoshi
    Ueno, Nobuhiro
    Tanabe, Hiroki
    Yuzawa, Sayaka
    Fujiya, Mikihiro
    BMC GASTROENTEROLOGY, 2021, 21 (01)
  • [49] HEALTHCARE SERVICE UTILIZATION AND COSTS OF CERTOLIZUMAB PEGOL VERSUS INFLIXIMAB TREATMENT IN PATIENTS WITH CROHN'S DISEASE
    Tkacz, Joseph
    Lee, Edward
    Low, Robert
    Stark, Jeffrey
    Yassine, Mohamed
    Brady, Brenna L.
    INFLAMMATORY BOWEL DISEASES, 2018, 24 : S15 - S15
  • [50] HEALTHCARE SERVICE UTILIZATION AND COSTS OF CERTOLIZUMAB PEGOL VERSUS INFLIXIMAB TREATMENT IN PATIENTS WITH CROHN'S DISEASE
    Tkacz, Joseph
    Lee, Edward
    Low, Robert
    Stark, Jeffrey
    Yassine, Mohamed
    Brady, Brenna L.
    GASTROENTEROLOGY, 2018, 154 (01) : S22 - S22
12345